CHU de Strasbourg (HUS)

The trials here

What the trial at this site is about, from its registry record.

Conditions

• Multiple myeloma

Running trials

• Active, not recruiting

  Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

  NCT06353022· Phase 2· Nantes University Hospital· Source